HEARTSCIENCES INC (HSCS) Fundamental Analysis & Valuation
NASDAQ:HSCS • US42254E3027
Current stock price
2.55 USD
-0.02 (-0.78%)
Last:
This HSCS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. HSCS Profitability Analysis
1.1 Basic Checks
- HSCS had negative earnings in the past year.
- In the past year HSCS has reported a negative cash flow from operations.
- In the past 5 years HSCS always reported negative net income.
- In the past 5 years HSCS always reported negative operating cash flow.
1.2 Ratios
- HSCS has a worse Return On Assets (-150.70%) than 88.04% of its industry peers.
- The Return On Equity of HSCS (-216.05%) is worse than 76.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -150.7% | ||
| ROE | -216.05% | ||
| ROIC | N/A |
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HSCS has a Gross Margin of 57.47%. This is comparable to the rest of the industry: HSCS outperforms 58.15% of its industry peers.
- In the last couple of years the Gross Margin of HSCS has grown nicely.
- The Profit Margin and Operating Margin are not available for HSCS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.47% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
2. HSCS Health Analysis
2.1 Basic Checks
- HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- HSCS has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, HSCS has less shares outstanding
- The debt/assets ratio for HSCS is higher compared to a year ago.
2.2 Solvency
- HSCS has an Altman-Z score of -20.19. This is a bad value and indicates that HSCS is not financially healthy and even has some risk of bankruptcy.
- HSCS has a worse Altman-Z score (-20.19) than 89.67% of its industry peers.
- There is no outstanding debt for HSCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.19 |
ROIC/WACCN/A
WACC10.01%
2.3 Liquidity
- HSCS has a Current Ratio of 2.42. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
- HSCS's Current ratio of 2.42 is in line compared to the rest of the industry. HSCS outperforms 46.20% of its industry peers.
- HSCS has a Quick Ratio of 2.00. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.00, HSCS perfoms like the industry average, outperforming 51.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.42 | ||
| Quick Ratio | 2 |
3. HSCS Growth Analysis
3.1 Past
- HSCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.25%, which is quite impressive.
- The Revenue for HSCS has decreased by -76.34% in the past year. This is quite bad
- The Revenue for HSCS have been decreasing by -41.50% on average. This is quite bad
EPS 1Y (TTM)74.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.56%
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 28.44% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y59.35%
EPS Next 2Y28.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. HSCS Valuation Analysis
4.1 Price/Earnings Ratio
- HSCS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSCS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- HSCS's earnings are expected to grow with 28.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.44%
EPS Next 3YN/A
5. HSCS Dividend Analysis
5.1 Amount
- No dividends for HSCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
HSCS Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:HSCS (3/20/2026, 8:00:01 PM)
2.55
-0.02 (-0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-12 2026-03-12
Earnings (Next)N/A N/A
Inst Owners6.23%
Inst Owner Change12.69%
Ins Owners3.59%
Ins Owner Change75.21%
Market Cap8.11M
Revenue(TTM)8.70K
Net Income(TTM)-9.04M
Analysts82.5
Price Target10.81 (323.92%)
Short Float %1.26%
Short Ratio1.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.14%
Min EPS beat(2)18.47%
Max EPS beat(2)57.81%
EPS beat(4)3
Avg EPS beat(4)22.01%
Min EPS beat(4)-6.31%
Max EPS beat(4)57.81%
EPS beat(8)5
Avg EPS beat(8)-35.56%
EPS beat(12)7
Avg EPS beat(12)-27.5%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)59.13%
EPS NY rev (1m)0%
EPS NY rev (3m)41.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 932.07 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.94 | ||
| P/tB | 3.44 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.88
EYN/A
EPS(NY)-3.28
Fwd EYN/A
FCF(TTM)-2.37
FCFYN/A
OCF(TTM)-2.36
OCFYN/A
SpS0
BVpS1.32
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -150.7% | ||
| ROE | -216.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.47% | ||
| FCFM | N/A |
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 145.29% | ||
| Cap/Sales | 460.92% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.42 | ||
| Quick Ratio | 2 | ||
| Altman-Z | -20.19 |
F-Score3
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)199.15%
Cap/Depr(5y)121.34%
Cap/Sales(3y)570.65%
Cap/Sales(5y)345.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.56%
EPS Next Y59.35%
EPS Next 2Y28.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.17%
OCF growth 3YN/A
OCF growth 5YN/A
HEARTSCIENCES INC / HSCS Fundamental Analysis FAQ
What is the fundamental rating for HSCS stock?
ChartMill assigns a fundamental rating of 2 / 10 to HSCS.
Can you provide the valuation status for HEARTSCIENCES INC?
ChartMill assigns a valuation rating of 1 / 10 to HEARTSCIENCES INC (HSCS). This can be considered as Overvalued.
What is the profitability of HSCS stock?
HEARTSCIENCES INC (HSCS) has a profitability rating of 1 / 10.